JP2015501656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501656A5 JP2015501656A5 JP2014547351A JP2014547351A JP2015501656A5 JP 2015501656 A5 JP2015501656 A5 JP 2015501656A5 JP 2014547351 A JP2014547351 A JP 2014547351A JP 2014547351 A JP2014547351 A JP 2014547351A JP 2015501656 A5 JP2015501656 A5 JP 2015501656A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- acid molecule
- composition
- homologous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 81
- 108020004707 nucleic acids Proteins 0.000 claims description 61
- 102000039446 nucleic acids Human genes 0.000 claims description 61
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 239000012634 fragment Substances 0.000 claims description 35
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 12
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims description 12
- 230000002163 immunogen Effects 0.000 claims description 10
- 101710202686 Penicillin-sensitive transpeptidase Proteins 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 8
- 108091026890 Coding region Proteins 0.000 claims description 6
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 238000004520 electroporation Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 description 11
- 230000000069 prophylactic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569727P | 2011-12-12 | 2011-12-12 | |
| US61/569,727 | 2011-12-12 | ||
| PCT/US2012/069014 WO2013090294A1 (en) | 2011-12-12 | 2012-12-11 | Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018072242A Division JP2018102319A (ja) | 2011-12-12 | 2018-04-04 | ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501656A JP2015501656A (ja) | 2015-01-19 |
| JP2015501656A5 true JP2015501656A5 (enExample) | 2016-01-21 |
| JP6407028B2 JP6407028B2 (ja) | 2018-10-17 |
Family
ID=48613118
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547351A Expired - Fee Related JP6407028B2 (ja) | 2011-12-12 | 2012-12-11 | ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用 |
| JP2018072242A Pending JP2018102319A (ja) | 2011-12-12 | 2018-04-04 | ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018072242A Pending JP2018102319A (ja) | 2011-12-12 | 2018-04-04 | ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9750795B2 (enExample) |
| EP (1) | EP2791362B1 (enExample) |
| JP (2) | JP6407028B2 (enExample) |
| KR (1) | KR20140116095A (enExample) |
| AU (1) | AU2012352455B2 (enExample) |
| CA (1) | CA2858884A1 (enExample) |
| WO (1) | WO2013090294A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110189217A1 (en) | 2008-06-26 | 2011-08-04 | Barry Michael A | Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| JP6407028B2 (ja) | 2011-12-12 | 2018-10-17 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用 |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
| EP2971165A4 (en) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS |
| WO2014152031A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Ribonucleic acid purification |
| US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
| CA2917348A1 (en) | 2013-07-11 | 2015-01-15 | Moderna Therapeutics, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| WO2015196128A2 (en) | 2014-06-19 | 2015-12-23 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| US10407683B2 (en) | 2014-07-16 | 2019-09-10 | Modernatx, Inc. | Circular polynucleotides |
| WO2017049286A1 (en) | 2015-09-17 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucleotides containing a morpholino linker |
| EP3350333B2 (en) | 2015-09-17 | 2025-08-06 | ModernaTX, Inc. | Polynucleotides containing a stabilizing tail region |
| WO2017223176A1 (en) | 2016-06-24 | 2017-12-28 | Modernatx, Inc. | Methods and apparatus for filtration |
| IL309370B2 (en) | 2021-06-16 | 2025-07-01 | Conti Spe Llc | Mechanically stacked solar transmissive cells or modules |
| US12414402B1 (en) | 2025-01-03 | 2025-09-09 | Conti Innovation Center, Llc | Optimizing cadmium (CD) alloy solar cells with sputtered copper-dopped zinc telluride (ZNTE:CU) back contacts in the presence of hydrogen |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1006493A (en) | 1911-02-27 | 1911-10-24 | Alwin Mfg Company | Folding perambulator or go-cart. |
| US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US5223424A (en) | 1985-09-06 | 1993-06-29 | Prutech Research And Development | Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence |
| US5310668A (en) | 1986-06-20 | 1994-05-10 | Merck & Co., Inc. | Varicella-zoster virus as a live recombinant vaccine |
| US5242829A (en) | 1986-09-23 | 1993-09-07 | Therion Biologics Corporation | Recombinant pseudorabies virus |
| IL86583A0 (en) | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
| US5294441A (en) | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
| US5387744A (en) | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
| US5112749A (en) | 1987-10-02 | 1992-05-12 | Praxis Biologics, Inc. | Vaccines for the malaria circumsporozoite protein |
| WO1990010693A1 (en) | 1989-03-08 | 1990-09-20 | Health Research, Inc. | Recombinant poxvirus host selection system |
| US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| ES2090129T3 (es) | 1989-03-31 | 1996-10-16 | Univ Washington | Vacunas que contienen microorganismos tipo phop avirulentos. |
| EP0431668B1 (en) | 1989-12-04 | 1995-02-15 | Akzo Nobel N.V. | Recombinant herpesvirus of turkeys and live vector vaccines derived thereof |
| US5294548A (en) | 1990-04-02 | 1994-03-15 | American Biogenetic Sciences, Inc | Recombianant Hepatitis a virus |
| US5462734A (en) | 1990-11-02 | 1995-10-31 | Wisconsin Alumni Research Foundation | Bovine herpesvirus vaccine and method of using same |
| US5240703A (en) | 1991-03-01 | 1993-08-31 | Syntro Corporation | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof |
| CA2063316A1 (en) | 1991-03-19 | 1992-09-20 | Larry C. Blaszczak | Dna and amino acid sequence of penicillin binding protein 2a from staphylococcus aureus strain 27r and derivatives for use in purification thereof and assay for compounds effective against methicillin resistant organisms |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
| HU219767B (hu) | 1993-01-26 | 2001-07-30 | Leslie R. Coney | Készítmények és eljárások genetikai anyag sejtbe történő beviteléhez |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| CA2285056C (en) | 1997-04-03 | 2004-12-14 | Iacob Mathiesen | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
| AU8444798A (en) | 1997-06-30 | 1999-01-25 | Centre National De La Recherche Scientifique | Improved method for transferring nucleic acid into the striped muscle and combination therefor |
| US7060458B1 (en) * | 1997-08-14 | 2006-06-13 | Wyeth | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| US6697669B2 (en) | 1998-07-13 | 2004-02-24 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| EP1233974A4 (en) | 1999-09-01 | 2004-09-22 | Human Genome Sciences Inc | GENES AND POLYPEPTIDEDES 37 I STAPHYLOCOCCUS AUREUS / I |
| AU2002211490A1 (en) | 2000-10-04 | 2002-04-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| JP3543326B2 (ja) | 2001-08-30 | 2004-07-14 | ソニー株式会社 | 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| MXPA05004860A (es) | 2002-11-04 | 2005-08-18 | Advisys Inc | Promotores musculares sinteticos con actividades que exceden las secuencias reguladoras de origen natural en las celulas cardiacas. |
| WO2004108260A2 (en) | 2003-05-30 | 2004-12-16 | Advisys, Inc. | Devices and methods for biomaterial production |
| NZ570709A (en) | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
| CA3057039C (en) * | 2006-07-28 | 2023-02-28 | The Trustees Of The University Of Pennsylvania | Hiv consensus envelope sequences and methods for using same |
| WO2008154101A1 (en) | 2007-06-06 | 2008-12-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Psm peptides as vaccine targets against methicillin-resistant staphylococcus aureus |
| KR101686942B1 (ko) * | 2008-01-11 | 2016-12-28 | 이노비오 파마수티컬즈, 인크. | 뎅기 바이러스 다중 서브타입에 대항하는 신규한 백신 |
| JP2009222712A (ja) * | 2008-02-21 | 2009-10-01 | Univ Nagoya | メチシリン耐性ブドウ球菌の検出法、検出用試薬及び検出用キット |
| US20110189217A1 (en) * | 2008-06-26 | 2011-08-04 | Barry Michael A | Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance |
| EP2358733B1 (en) | 2008-11-17 | 2015-07-08 | Inovio Pharmaceuticals, Inc. | Antigens that elicit immune response against flavivirus and methods of using same |
| TW201021853A (en) | 2008-11-17 | 2010-06-16 | Enzon Pharmaceuticals Inc | Releasable cationic lipids for nucleic acids delivery systems |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| JP6407028B2 (ja) | 2011-12-12 | 2018-10-17 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用 |
| GB2504774A (en) | 2012-08-10 | 2014-02-12 | Munster Simms Eng Ltd | Diaphragm pump with integral motor housing and rear pump housing |
| TWI548337B (zh) | 2015-10-16 | 2016-09-01 | 技嘉科技股份有限公司 | 散熱模組、顯示卡組件及電子裝置 |
-
2012
- 2012-12-11 JP JP2014547351A patent/JP6407028B2/ja not_active Expired - Fee Related
- 2012-12-11 US US14/365,071 patent/US9750795B2/en active Active
- 2012-12-11 AU AU2012352455A patent/AU2012352455B2/en not_active Ceased
- 2012-12-11 KR KR1020147019093A patent/KR20140116095A/ko not_active Ceased
- 2012-12-11 WO PCT/US2012/069014 patent/WO2013090294A1/en not_active Ceased
- 2012-12-11 CA CA2858884A patent/CA2858884A1/en not_active Abandoned
- 2012-12-11 EP EP12858266.5A patent/EP2791362B1/en not_active Not-in-force
-
2017
- 2017-08-14 US US15/675,823 patent/US10064931B2/en active Active
-
2018
- 2018-04-04 JP JP2018072242A patent/JP2018102319A/ja active Pending
- 2018-08-24 US US16/111,267 patent/US10980870B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015501656A5 (enExample) | ||
| JP2014507146A5 (enExample) | ||
| JP2019506175A5 (enExample) | ||
| JP2015501840A5 (enExample) | ||
| RU2017104529A (ru) | Композиции neisseria meningitidis и способы их применения | |
| JP2012515557A5 (enExample) | ||
| TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
| NZ602943A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| JP2015514132A5 (enExample) | ||
| JP2012126742A5 (enExample) | ||
| JP2017532966A5 (enExample) | ||
| EP2470670A4 (en) | COAGULATION FACTOR VII COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF | |
| JP2014534202A5 (enExample) | ||
| MX358725B (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| JP2016500250A5 (enExample) | ||
| JP2014500724A5 (enExample) | ||
| NZ628126A (en) | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases | |
| JP2013507907A5 (enExample) | ||
| JP2013523718A5 (enExample) | ||
| NZ701881A (en) | Vaccines for hsv-2 | |
| IL276210B2 (en) | Mers-cov vaccine | |
| JP2012501959A5 (enExample) | ||
| MX2009008118A (es) | Polipeptido e2 del virus del papiloma usado para vacunacion. | |
| JP2015500827A5 (enExample) | ||
| JP2012516140A5 (enExample) |